Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
17. Januar 2024 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an agreement with a Japanese distributor for the...
Precipio & ADS Biotec Launch Seven Beta sites for IV-Cell™
06. Oktober 2020 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), along with its partner ADS Biotec announce the launch of the beta phase...
Precipio & ADS Biotec Sign Global Distribution Agreement for IV-Cell™
20. August 2020 13:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has signed an exclusive global distribution agreement with ADS...
Clinical Validations for IV-Cell™ and HemeScreen™ Completed
26. September 2019 10:53 ET
|
Precipio, Inc.
Orders expected from several major labs both domestically and internationally NEW HAVEN, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO),...
Global Expansion Efforts Begin Yielding Results
22. Juli 2019 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., July 22, 2019 (GLOBE NEWSWIRE) -- Specialty Diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that in conjunction with its global expansion efforts, it has begun...
Precipio Identifies Manufacturer for its IV-Cell Media
09. April 2019 09:15 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 09, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced today that it is negotiating a definitive agreement with a manufacturer to...